Direct-to-Patient Site

Science 37’s Direct-to-Patient Site is the industry’s first and only FDA-inspected decentralized clinical trial platform that brings research directly to patients’ homes. It enables sponsors to reach 100% of their target population by eliminating geographic barriers and delivering high-quality care, data collection, and regulatory compliance through a virtual site model.

Features

• FDA-Inspected Infrastructure: Validated across multiple Phase 3 trials with no findings or objections.
• Nationwide Medical Licensure: Coverage across all 50 U.S. states for seamless trial execution.
• Single 1572 and IRB Submission: Streamlined regulatory process for faster trial start-up.
• In-Home Study Visits: Conducted by research-grade nurses with full coordination and oversight.
• Direct-to-Patient Logistics: Includes shipment of investigational products, lab kits, and supplies to patient homes.
• Remote Investigator Oversight: Ensures safety and compliance through real-time monitoring and data access.
• Protocol-Adherent Execution: Maintains full chain of custody and procedural integrity during home visits.

Capabilities

• Decentralized Trial Delivery: Enables participation from any location, removing the need for travel.
• Broad Therapeutic Coverage: Supports studies across cardiology, dermatology, neurology, oncology, rare diseases, and more.
• Scalable Operations: Suitable for Phase 2–4 interventional and observational trials, including long-term follow-up.
• Real-Time Data Collection: Facilitates immediate access to clinical data for investigators and sponsors.
• Patient-Centric Design: Enhances comfort and accessibility by conducting visits in familiar environments.
• Trusted Experience: Over 185 clinical trials supported and 13,000+ in-home visits delivered.

Benefits

• Expanded Patient Access: Reaches populations beyond traditional site catchment areas.
• Accelerated Enrollment: Reduces delays by simplifying logistics and regulatory processes.
• Improved Retention: Enhances patient satisfaction and engagement through personalized care.
• High-Quality Data: Maintains rigorous standards for data integrity and protocol compliance.
• Operational Efficiency: Streamlines trial workflows and reduces site burden.
• Inclusive Research: Enables participation from diverse and underserved communities.